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Abstract
Background: The alkylating agent Dacarbazine (DTIC) has been used in the treatment of melanoma for decades, but 
when used as a monotherapy for cancer only moderate response rates are achieved. Recently, the clinical use of 
Temozolomide (TMZ) has become the more commonly used analog of DTIC-related oral agents because of its greater 
bioavailability and ability to cross the blood brain barrier. The response rates achieved by TMZ are also unsatisfactory, 
so there is great interest in identifying compounds that could be used in combination therapy. We have previously 
demonstrated that the bioflavonoid quercetin (Qct) promoted a p53-mediated response and sensitized melanoma to 
DTIC. Here we demonstrate that Qct also sensitizes cells to TMZ and propose a mechanism that involves the 
modulation of a truncated p53 family member, ΔNp73.
Methods: DB-1 melanoma (p53 wildtype), and SK Mel 28 (p53 mutant) cell lines were treated with TMZ (400 μM) for 48 
hrs followed by Qct (75 μM) for 24 hrs. Cell death was determined by Annexin V-FITC staining and 
immunocytochemical analysis was carried out to determine protein translocation.
Results: After treatment with TMZ, DB-1 cells demonstrated increased phosphorylation of Ataxia telangiectasia 
mutated (ATM) and p53. However, the cells were resistant to TMZ-induced apoptosis and the resistance was associated 
with an increase in nuclear localization of ΔNp73. Qct treatment in combination with TMZ abolished drug insensitivity 
and caused a more than additive induction of apoptosis compared to either treatment alone. Treatment with Qct, 
caused redistribution of ΔNp73 into the cytoplasm and nucleus, which has been associated with increased p53 
transcriptional activity. Knockdown of ΔNp73 restored PARP cleavage in the TMZ treated cells, confirming its anti-
apoptotic role. The response to treatment was predominantly p53 mediated as the p53 mutant SK Mel 28 cells showed 
no significant enhancement of apoptosis.
Conclusion: This study demonstrates that Qct can sensitize cells to TMZ and that the mechanisms of sensitization 
involve modulation of p53 family members.
Background
Melanoma has been categorized as the most aggressive
form of skin cancer [1] and its incidence has increased
worldwide over the last 50 years. In the United States,
this form of cancer is the fifth and sixth most common
cancer in men and women, respectively, and has an esti-
mated average lifetime risk of 1 in 75 [2,3]. Dacarbazine
(DTIC) is considered one of the most effective chemo-
therapies for metastatic melanoma, with response rates
ranging between 10-20%; however, lower response rates
(7-8%) and a 6-year survival rate of 2% have been
reported [4]. Unfortunately, the poor response of mela-
noma to chemotherapy is also accompanied by systemic
toxicities that lead to poor quality of life for patients.
Temozolomide (TMZ), a DTIC derivative, is a second-
generation imidazotetrazine alkylating agent that is
hydrolyzed to the active metabolite 5-(3,3-methyltriazen-
1-yl) imidazole-4-carboxamide which further decom-
poses into a DNA methylating species [5]. TMZ repre-
sents a new analogue of DTIC with more desirable
properties because it can enter the cerebrospinal fluid
and does not require hepatic metabolism for activation. It
has the same cytotoxic activity as DTIC, which results
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from its ability to add a methyl group to the O6 position of
guanine in genomic DNA [6]. TMZ has been approved
for the treatment of brain metastasis and has demon-
strated clinical activity against melanoma, but overall it
yields response rates similar to that of DTIC.
To improve response rates without increasing toxici-
ties, various biological therapies have been considered for
use in combination with this class of chemotherapy. Poly-
phenol compounds are of particular interest in combina-
tion therapies because they can be readily activated by
oxidases overexpressed in many tumors [7,8]. Quercetin,
for example, is a naturally occurring polyphenol that
becomes activated in tyrosinase expressing cells such as
melanoma. Qct is an established anticancer compound
that exhibits anti-proliferative properties in numerous
cancer cell lines [9] and animal models [10]. Enzymatic
activation of Qct by tyrosinase specifically enhances its
anti-tumor activity in melanoma cells [11] and increases
the effectiveness of additional cytotoxic compounds [12].
The chemosensitizing effect of Qct has yet to be uti-
lized clinically, but its use as an adjuvant to conventional
chemotherapy could potentially enhance the therapeutic
ratio in melanoma cells by increasing tumor cell kill in
tyrosinase expressing cells while having little effect on
normal tissue toxicity. The mechanism of tumor cell kill
by chemotherapeutic drugs is in part through the induc-
tion of apoptosis [13]. Apoptosis is largely mediated by
the tumor suppressor gene p53, and numerous cancer cell
models indicate that chemosensitivity is positively corre-
lated with the induction of p53. In most melanoma cells
the p53 gene is wildtype, which further supports the use
of apoptosis inducing agents in the treatment of mela-
noma.
In melanoma, p53 protein levels increase with tumori-
genesis and development [14], and despite the presence
of functional p53, melanoma is generally regarded as a
chemoresistant tumor type. One possible explanation for
the development of the resistant phenotype could be
through the upregulation of p53 antagonists, such as
truncated p53 family members [14]. The p73 protein is a
homolog of p53, and has antitumor effects in various can-
cerous cells, which are mediated through cell cycle arrest
and the induction of pro-apoptotic target genes [15].
However, several isoforms of p73 exist, including a trun-
cated form that act as a p53 antagonist. The N terminal
truncated form (ΔNp73) acts as an antagonist to p53 by
localizing to the nucleus and preventing transcription of
p53-responsive genes, such as Bax [16]. Here, we demon-
strate that ΔNp73 is induced by TMZ and prevents p53-
mediated apoptosis and cell death. Chemoresistance is
reversed by Qct, and we therefore propose a mechanism
by which Qct abrogates the inhibitory effects of ΔNp73
by modulating the protein and altering its localization.
Methods
DB-1 melanoma cells were developed from lymph node
biopsies from metastatic patients at Thomas Jefferson
University, Philadelphia [17]. The cells were grown in α-
minimum essential medium (MEM) complete medium in
a 5% CO2  incubator at 37°C and stably express the
pcDNA3 vector as previously described [12]. SK Mel 28
(mutant for p53) and SK Mel 5 (wild type for p53) mela-
noma cell lines were obtained from American Tissue Cul-
ture Collections (Rockville, MD, USA). Quercetin (3, 3, 4,
5, 7-pentahydroxy flavone), α-MEM and dimethylsulfox-
ide (DMSO) were purchased from Sigma, (St. Louis, MO,
USA). TMZ was a kind gift from The Developmental
Therapeutics Program, National Cancer Institute
(Bethesda, MD, USA). Antibodies for Bax, p53 and Tyro-
sinase for western blotting were obtained from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies
for phosphorylated p53 (at ser 15, 37, 392), phosphory-
lated ATM (ser 1981), DNApk and PARP were obtained
from Cell Signaling (Danvers, MA, USA). Antibody for
GAPDH was purchased from Millipore-Chemicon (San
Francisco, CA, USA). p73 antibody for western blotting
and immunocytochemistry (ICC) was obtained from
IMGENEX (San Diego, CA, USA). Sterile DMSO (0.1%)
dissolved in α-MEM complete medium was used as vehi-
cle. Quercetin and TMZ were prepared in sterile filtered
DMSO.
TMZ and Qct treatment
TMZ (20 mg/ml) was dissolved in DMSO and then dis-
solved in α-MEM complete medium and sterile filtered
after adjusting the pH to 7.4. For combination treatments
the cell lines were treated with TMZ 400 μM for 48 hr fol-
lowed by Qct 75 μM for 24 hr.
Western blotting
Cell lysates were electrophoresed in 7 and 10% NUPAGE
gels (Invitrogen Corp., CA, USA). Separated proteins
were electrophoretically transferred to Hybond PVDF
membrane (Amersham Pharmacia Biotech, UK) and the
membrane was blocked for 1 hr by incubating the mem-
brane in I-block (Tropix kit, Applied Biosystems, CA,
USA). Primary antibodies were used at the dilutions
which the manufacturers suggested. ALP conjugated goat
anti-rabbit IgG was used at a dilution of 1:10000 for anti-
bodies for phospho-p53, DNApk, Bax and PARP
whereas, anti-mouse IgG was used for Total p53, Total
p73, phospho-ATM and GAPDH at a dilution of 1:10000.
Western detection was carried out using CDP star from
Tropix kit, Applied Biosystems, CA, USA.
Annexin V-FITC staining
The p53 wild type and mutant cell lines were grown up to
50% confluency and were treated as mentioned above.Thangasamy et al. BMC Cancer 2010, 10:282
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Apoptosis was determined using Fluorescein isothiocya-
nate-conjugated Annexin V (Annexin V-FITC)/Propid-
ium Iodide (PI) apoptosis detection kit (R&D systems,
Minneapolis, MN, USA) as per manufacturer's instruc-
tions. Approximately 5 × 105 cells were resuspended in
100 μl of 1× binding buffer, 1 μl of Annexin V-FITC and
10 μl of propidium iodide. After 15 min incubation at
room temperature in the dark, 400 μl of 1× binding buffer
was added and the cells positive for Annexin V-FITC
and/or PI were analyzed using a BD FACS flow cytome-
ter.
RNA isolation and RT-PCR
Homogenization of cells and isolation of RNA were per-
formed using QIAshredder spin columns and an RNeasy
Kit as instructed by the manufacturer (Qiagen, Valencia,
CA). 1 μg of RNA was reverse transcribed using a Super
Script III Kit as instructed by the manufacturer (Invitro-
gen, Carlsbad, CA) and diluted 1:5 for subsequent analy-
sis. The following PCR reaction mix was used: 5 ul of
diluted cDNA, 1 ul of mixed forward and reverse primers
(10 uM each), 12.5 ul SYBR Green (Qiagen), and nucle-
ase-free water to a final volume of 25 ul. For non-quanti-
tative PCR, cDNA was amplified for thirty cycles. Forty
cycles of quantitative PCR were performed (95°C for 15
seconds, 54°C for 30 seconds, 72°C for 30 seconds) using
an iQ5 Real-Time PCR Detection System (BioRad, Her-
cules, CA) and run on a 1% agarose gel. Real-time PCRs
were run in triplicate for each cDNA sample using an iQ5
Real-Time PCR Detection System. Forty cycles of PCR
were performed (as described above) with fluorescence
detection during the 72°C step at each cycle. The data
were analyzed using the 2-ΔΔCt method [18], and results
were normalized to S15, which remains unchanged in
response to treatment. Normalized values were plotted as
relative fold over untreated. The following primers were
purchased from Integrated DNA Technologies (Coral-
ville, IA, USA): S15 [19] transcriptionally active p73
(TAp73) [20] and ΔNp73 [21].
Immunocytochemistry
The cells were grown on cover slips in 100 mm tissue cul-
ture dishes and were treated with TMZ and Qct as men-
tioned above. The cover slips were placed in 6 well dishes
and washed with PBS and fixed with 95% ethanol and 5%
glacial acetic acid for 5 min. The slides were rinsed with
PBS and were incubated with 0.5% of Triton X-100 in PBS
for 10 min to permeabilize the membranes and rinsed
again. After blocking the endogenous peroxidase with 3%
hydrogen peroxide (H2O2) in PBS for 20 min the cover
slips were processed according to staining procedure of
the manufacturer's protocol for Histostain plus kits,
Zymed Laboratories (Invitrogen, CA, USA). Total p73
antibody was used in the dilution of 1:250.
siRNA transfection
siRNA transfection was carried out according to manu-
facturer's protocol (Invitrogen, CA, USA). Cells were
grown up to 50% confluence in antibiotic free medium in
100 mm dishes. Stealth RNAi for p73 at varying concen-
trations (1 nM-50 nM) was diluted in 1.5 ml OPTI-MEM
I reduced serum. 30 μl of Lipofectamine™ 2000 was
diluted in 1.5 ml OPTI-MEM I reduced serum medium,
mixed gently. After 5 min incubation at RT, diluted oli-
gomer was combined with diluted Lipofectamine™ 2000,
mixed gently and incubated at room temp for 20 min.
The oligomer-Lipofectamine™ 2000 complexes were
added to each plate in OPTI-MEM I reduced serum
medium by mixing gently and by rocking the plate back
and forth. After 6 hrs incubation in a 5% CO2 incubator at
37°C, the plates were subjected to TMZ treatment for 48
hrs without removing the complexes. BLOCK-iT Fluores-
cent oligomer was used as positive control.
Transient transfection with Tyrosinase
DB-1 cells were transiently transfected with 6 μg of tyro-
sinase or pcDNA3 DNA using Lipofectamine™ 2000 in
serum free OPTI-MEM medium for 5 hr followed by
leaving the complex in Neomycin containing α MEM
complete medium for at least 18 hrs as demonstrated pre-
viously [12].
Results
TMZ and Qct induce Cell Death
To establish a dose response to TMZ, DB-1 cells were
treated with varying concentrations of TMZ (0-400 μM)
for 48 hrs and the amount of cell death (apoptosis and
necrosis) was determined by Annexin V-FITC/PI double
staining and flow cytometry analysis. Consistent with a
chemoresistant melanoma phenotype, DB-1 cells were
resistant to TMZ-induced cell death at concentrations
lower than 100 μM (Figure 1A). In contrast, Qct treat-
ment (0-100 μM) resulted in dose dependent cell death at
all concentrations studied (Figure 1B).
For subsequent combination studies, a concentration of
400 μM TMZ plus 75 μM Qct was used as those concen-
trations individually resulted in a distinguishable degree
of apoptotic cell death (Figure 1C). To treat cells in com-
bination TMZ was administered for 48 hrs followed by 24
hrs of Qct. In DB-1 cells treatment with TMZ or Qct
induced 9.2% (± 0.4%) or 11.4% (± 0.4%) apoptosis (lower
right quadrant of flow-cytometeric scatter plot, Figure
1E), respectively (Figure 1C). However, the combination
treatment of TMZ plus Qct induced 34.25% (± 2.6%)
apoptosis, which was greater than additive in these cell
lines. Late apoptosis or necrosis (upper right quadrant of
flow-cytometeric scatter plot, Figure 1E) was also
increased in a more than additive manner. Apoptosis
analysis was also carried out in p53 mutant SK Mel 28Thangasamy et al. BMC Cancer 2010, 10:282
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Figure 1 The induction of apoptosis by TMZ, Qct or combination treatment. DB-1 cell lines were subjected to varying dose of A) TMZ treatment 
(0-400 μM) for 48 hrs or B) Qct treatment for 24 hrs (0-100 μM). The cells were subjected to apoptotic analysis by Annexin/FITC staining by using BD 
FACS flow cytometer and the percentage of apoptosis was determined. C) The stacked percentages of apoptotic cells after TMZ treatment in DB-1 or 
D) SK Mel 28 cell lines Results are mean of duplicate experiments. E) Representative flow cytometric scatter plots of DB-1 cells. Early apoptotic cells 
can be visualized in the lower right quadrant, while late apoptotic/necrotic cells are shown in the upper right.
EThangasamy et al. BMC Cancer 2010, 10:282
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cells and there was no significant increase in cell death
across treatments (Figure 1D). Representative flow
cytometeric scatter plots for DB-1 cells can be seen in
Figure 1E.
DNA Damage Response
We next investigated the effect of Qct and TMZ on the
DNA damage response. ATM is a protein kinase that is
rapidly activated by DNA double strand breaks (DSBs)
and is known to phosphorylate downstream target sub-
strates such as p53. An increase in ATM phosphorylation
at Ser 1981 (p-ATM) was observed in DB-1 cell lines
treated with TMZ and a slight increase in p-ATM was
observed by Qct treatment (Figure 2). The greatest
increase in p-ATM was observed in the combination
treatment. A similar increase in p-ATM was observed in
SK Mel 28 cells, but Qct did not measurably activate this
protein. Induction of DNApk, another DNA repair pro-
tein, was also observed in all the treatment groups (Figure
2).
Because ATM was activated we investigated the effect
of treatment on post-translational modification of p53 by
evaluating phosphorylation of its serine moieties. In the
DB-1 cells phosphorylation of p53 at serine 15, 37 and
392 was increased following treatment with TMZ or
TMZ plus Qct (Figure 3A). The expression of total p53
also increased accordingly. We confirmed the sensitiza-
tion effect in SK Mel 5, another p53 wild type cell line
(Figure 3B). However, there was a minimal activation of
p53 at serine 15 in SK Mel 28 cells (Figure 3C) and phos-
phorylation at other sites could not be detected (data not
shown). No changes in the levels of total p53 were
detected in the SK Mel 28 cells.
Abrogation of apoptosis by ΔNp73
The effect of the treatments on the proteins downstream
of p53, including Bax and cleaved PARP were also investi-
gated (Figure 4). The levels of apoptosis (Figure 1C),
cleaved PARP and caspase 3 (Figure 4A and 4B) did not
correlate with the increased levels of p-ATM and phos-
pho-p53 (Figures 2 and 3), indicating that signaling
between p53 and its downstream targets was attenuated
Figure 2 The effect of TMZ, Qct or combination treatment on 
DNA Damage Response proteins. Western blot analysis after treat-
ment with vehicle (DMSO), TMZ 400 μM for 48 hrs followed by Qct 75 
μM for 24 hrs. A) DB-1 or B) SK Mel 28 cell lines.
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Figure 3 The effect of TMZ, Qct or combination treatment on to-
tal p53 and phospho-p53. Western blot analysis after treatment with 
vehicle (DMSO), TMZ 400 μM for 48 hrs followed by Qct 75 μM for 24 
hrs. A) DB-1 or B) SK Mel 5 and C) SK Mel 28 cell lines. *indicates loading 
control for the different blots shown.
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Figure 4 The effect of TMZ, Qct or combination treatment on the 
levels of Bax and cleaved PARP. Western blots of A) DB-1 B) SK Mel 
5 and C) SK Mel 28 cells after treatment with vehicle (DMSO), TMZ 400 
μM for 48 hrs followed by Qct 75 μM for 24 hrs. *indicates loading con-
trol for the different blots shown.
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and thus blocked apoptosis. In the SK Mel 28 mutant cell
lines, there were no changes in total p53 levels (data not
shown) and levels of cleaved PARP (Figure 4C).
To investigate the abrogation of apoptosis in the cells
treated with TMZ we examined the role of p53 family
members, which have been shown to have inhibitory
effects on p53 function. The p73 gene is a homologue of
full length p53 and is involved in the transactivation of
p53 target genes and thereby causes an induction in
apoptosis and inhibition of cell proliferation [22]. Tran-
scriptionally active or TAp73 is the active isoform of p73
frequently expressed in human tumors [23] and inhibited
by either N terminally truncated p63 (ΔNp63) or ΔNp73.
ΔNp73 can also antagonize p53. We performed RT-PCR
for TAp73 and ΔNp73 to determine the isoforms
expressed in DB-1 and SK-Mel28 cells. The only detect-
able isoform in DB-1 cells was ΔNp73 (Figure 5A) so DB-
1 cells were used to further investigate the role of the p73
deletion mutant on apoptosis and chemoresistance. Fol-
lowing treatment with TMZ or the TMZ plus Qct combi-
nation there was an increase in the transcription of only
ΔNp73 (Figure 5B). Western blot analysis also revealed a
single band of increased protein levels of p73 in the DB-1
cells treated with TMZ alone or in combination with Qct
and there was no change in protein levels of p73 in the SK
Mel 28 cells (Figure 5C).
Qct alters distribution of ΔNp73
The localization of p73 plays a major role in its activity so
the effect of Qct on localization of p73 was investigated.
The full length transcriptionally active form of p73
(TAp73) is normally found in the nucleus and can induce
the transcription of downstream p53 target genes. How-
ever, when the ΔN form is in the nucleus, it can antago-
nize p53, which could be the reason why the levels of Bax
(Figure 4) did not correlate with the increased levels of
phospho-p53 (Figure 3) and the abrogation of apoptosis
in the TMZ-treated cells. Consistent with previous
reports of p73 localization, immunocytochemistry (ICC)
analysis revealed the nuclear staining in the untreated
cells that increased following treatment with TMZ (Fig-
ure 5D). In contrast, Qct treatment caused a re-distribu-
tion of ΔNp73 from the nucleus into cytoplasm as well as
in the nucleus. The re-distribution was also observed
with the combination treatment in DB-1 cell lines (Figure
5D) and indicates that the redistribution induced by Qct
can reduce the antagonist effect of ΔNp73.
To confirm the role of ΔNp73 in the attenuation of the
apoptotic response siRNA experiments were performed.
Naumann et al. [24] identified PARP cleavage as a hall-
mark of TMZ activity, so we investigated the effect of p73
siRNA on PARP levels. Treatment with TMZ resulted in
no significant cleavage of PARP compared to control (Fig-
ure 6B). However, incubation with p73 siRNA in TMZ-
treated cells knocked down the ΔNp73 protein levels and
resulted in an increase in the ratio of cleaved to uncleaved
PARP (Figure 6C). Taken together, these results con-
firmed the role of ΔNp73 as a p53 antagonist in the
response to TMZ and suggests that Qct promotes apop-
tosis by inducing the translocation of ΔNp73 out of the
nucleus.
Melanogenesis and ΔNp73
Tyrosinase activity is increased as melanoma tumors
develop and we have previously shown that tyrosinase
activity is associated with an increase in p53 [11,12].
Because p53 can transcriptionally activate p73, we inves-
tigated if tyrosinase overexpression could induce the
expression of p73. We transiently overexpressed tyrosi-
nase (Figure 6D) and observed an increase in the expres-
sion of p53 and its transcriptional target p73 (Figure 6D).
Therefore, tumorigenesis in melanoma, which coincides
with the overexpression of tyrosinase, could also be asso-
ciated with an increase in transcription of p53 antago-
nists and inducing resistance to chemotherapies.
Targeting these antagonists through compounds such as
quercetin could serve as an effective therapeutic or treat-
ment modifier by restoring p53 activity.
Discussion
DNA Damage Response
We have shown for the first time that Qct can affect the
cellular distribution of ΔNp73 and abrogate its anti-apop-
totic effects. We also demonstrated in melanoma that Qct
can affect the phosphorylation of p53, which is a key fac-
tor in mediating TMZ-induced apoptosis and a major
determinant of cancer cell response to TMZ [25]. TMZ
and DTIC methylate DNA at O6 methyl guanine residues
and cause mispairing with thymine and activation of
MutSa-dependent mismatch repair resulting in apoptosis
[26,27]. TMZ treatment during the present study caused
an induction in total p53 and phosphorylation of its ser-
ine residues at 15, 37 and 392. Studies by Mhaidat NM et
al. [28], illustrate that the sensitivity of melanoma cells to
TMZ was dependent on their p53 status and associated
G2/M arrest. We did confirm the central role of p53 with
TMZ treatment and further demonstrated TMZ is a
strong activator of ATM. ATM activation was enhanced
by Qct, which provides a mechanism for the activation
and stabilization of p53 while modulation of p73 likely
contributes to increased p53 activity.
Even though apoptosis is considered the major mecha-
nism of death by TMZ, [29] Qct also increased necrosis
and indicates that apoptosis might not be the only thera-
peutic outcome when using combination treatments. Cell
death reported here consists of an apoptotic fraction and
a second fraction of cells that consisted of late apoptosis
or necrosis. Necrosis as a mechanism of cell death canThangasamy et al. BMC Cancer 2010, 10:282
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not be ruled out and is line with another study in malig-
nant melanoma cells [30] that concluded TMZ-induced
O6-methyl guanine triggers the apoptotic as well as
necrotic pathway through the formation of DSBs. How-
ever, these pathways appear in part mediated by p53 as
the SK Mel 28 cells were relatively void of treatment-
induced cell death.
Abrogation of apoptosis by ΔNp73
Another mechanism of action of Qct appears to be
through the change in distribution of p73, allowing for an
increase in p53 nuclear activity. p73 belongs to the p53
family of proteins that exhibit sequence homology [31]
and they include p53, p63 and p73. Endogenous TAp73 is
upregulated in response to DNA damage or treatment
with chemotherapeutic drugs and provides antitumor
activity, while the upregulation of ΔNp73 promotes resis-
tance to these drugs [32]. The functionality of the p53
family members primarily depends on the nuclear local-
ization of p73. Studies demonstrate that the export of the
truncated form, ΔNp73, to the cytoplasm is a major
inducer of p53 functionality [33]. In earlier studies with
hepatocellular and cholangiocellular carcinomas, p73 was
reported to be confined to the nucleus [34,35]. It was also
found to be localized mainly in the nucleus of undifferen-
tiating neuroblastomas [36].
Our ICC study demonstrates that expression of ΔNp73
was confined to the nucleus in control melanoma cells
and this expression was even increased in the nucleus fol-
lowing TMZ treatment. Re-localization to the cytoplasm
could indicate a shift in the balance of p53 to p73 in the
nucleus and allow for transcription of p53 target genes, or
may indicate a functional change in p73 itself. Inoue et al.
Figure 5 Qct causes changes in p73 distribution. A) Non-quantitative PCR in DB-1 cells for TAp73 (Lane 1), ΔNp73 (Lane 2) and TAp73 positive con-
trol using SK Mel 28 cells (Lane 3) following treatment with TMZ. TAp73 was undetectable in the DB-1 cell line. B) Real time RT-PCR for ΔNp73 in DB-
1 cell lines treated with TMZ 400 μM for 48 hrs followed Qct 75 μM for 24 hrs. Results are Mean ± SEM of triplicate experiments in DB-1 cell lines. C) 
p73 expression by western blot analysis in DB-1 and SK Mel 28 cell lines treated with vehicle (DMSO), TMZ 400 μM for 48 hrs followed by Qct 75 μM 
for 24 hrs. D) Immunocytochemical analysis of p73 localization in DB-1 cell lines treated with vehicle (DMSO), TMZ 400 μM for 48 hrs followed by Qct 
75 μM for 24 hrs. Solid arrowheads indicate nuclear staining in cells without Qct treatment, while line-type arrowheads indicate cytoplasmic staining 
following Qct treatment.
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[37] demonstrated that p73 undergoes active export
which in part is mediated by nuclear export signal (NES)
localized in the C terminus. Qct can modify phosphory-
lation which is required for a functional NES [38]. The
change in localization could be therefore be related to
changes in nuclear import and export signals and related
changes in the overall distribution of p73.
The notion that p53 upregulates its own antagonist
provides a unique mechanism for averting functional p53
which is commonly found in melanoma. We have previ-
ously demonstrated that tyrosinase overexpression could
induce ROS which may induce p53 [11,12]. The upregula-
tion of p53 in a tumor would not be beneficial unless it
was transcribing an antagonistic protein such as ΔNp73.
Box et al [14] have also proposed that p53 and antago-
nists are increased with melanogenesis. Our results with
overexpression of tyrosinase are consistent with this
notion. Abrogation of the protective effect of p53 antago-
nists would provide a valuable target for tumor therapy,
especially since relatively non toxic molecules such as Qct
can affect its translocation and activity.
Conclusion
Our study is the first to demonstrate the effect of Qct on
p73 distribution and suggests p53 antagonists are associ-
ated with treatment escape. Qct added to p53 wildtype
melanoma cells abrogated chemoresistance and triggered
a more than additive induction of apoptosis, which was
associated with a cytosolic and nuclear localization of
p73. We also propose that during melanogenesis p53 is
induced in response to tyrosinase expression. The co-
expression of p53 antagonists could block the apoptotic
function of p53 and allow for continued development of
tumors. Therefore modifiers of p53 antagonists, such as
Qct, could serve as effective therapeutic or treatment
modifiers. Alternatively, Qct be used to target antagonists
for cancer prevention. The effect quercetin treatment on
cells that express both the TA and ΔNp73 isoforms is
unknown, but should be investigated.
Figure 6 Knockdown of p73 with siRNA restores PARP cleavage. Western blot analysis after transfection with p73 siRNA in DB-1 cell lines A) at 
basal level and B) after TMZ treatment and C) Quantification of p73 to GAPDH and Cleaved PARP relative to uncleaved PARP. D) Transient transfection 
of tyrosinase DNA in DB-1 cell lines and western blot analysis of p53 and 73 expression.
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